Tiziana Doses Last Patient in Phase 2 Foralumab Trial
Tiziana Life Sciences said it dosed the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
Tiziana Life Sciences initiated dosing for the final patient in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease. Enrollment is complete; topline results are expected in the first quarter of 2027. The placebo-controlled trial evaluates safety and potential efficacy, testing foralumab alone o
TLSA - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
TLSA - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease